Celgene prices $4.5B senior notes to help buy Juno; Health Affairs study says Novartis prices its CAR-T too high
→ Celgene $CELG has priced four series of senior unsecured notes for an aggregate of $4.5 billion, a portion of which will be used to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
